Overview

A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

Status:
Recruiting

Trial end date:
2022-12-30

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the safety and tolerability of TY-9591, with dose-escalation stage and dose-expansion stage.

Phase:

Phase 1

Details

Lead Sponsor:

TYK Medicines, Inc